Form 4: Indaptus Therapeutics Director Mark Gilbert Granted 12,500 Stock Options

Indaptus Therapeutics, Inc. Director Mark John Gilbert was granted 12,500 stock options with an exercise price of $0.33, vesting on June 10, 2026.

Summary

• Mark John Gilbert, a Director of Indaptus Therapeutics, Inc. (INDP), was granted 12,500 stock options.
• The transaction date for this grant was June 10, 2025.
• Each stock option has an exercise price of $0.33.
• The options will vest and become exercisable on June 10, 2026.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Mr. Gilbert directly beneficially owns 12,500 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued commitment from a director and aligns their interests with shareholders, which is generally viewed favorably.

Positives

• The grant of stock options to Director Mark John Gilbert aligns his financial interests with those of the shareholders, incentivizing long-term company performance.
• The exercise price of $0.33 per share is relatively low, potentially offering significant upside if the company's stock price appreciates.

Future Outlook

The granted stock options are scheduled to vest and become exercisable on June 10, 2026, indicating a future milestone for the reporting person's equity holdings.

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, specifically an equity grant to a director, which is a common practice across industries, including biotechnology, to incentivize leadership and align interests with shareholders.

Related Party Transactions

• Grant of 12,500 stock options to Mark John Gilbert, a Director of Indaptus Therapeutics, Inc., with an exercise price of $0.33.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can influence morale and retention of key personnel.

Next Steps

• The stock options will vest and become exercisable on June 10, 2026.

Key Dates

Keywords

Indaptus Therapeutics, INDP, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Beneficial Ownership